Host: Tiffany Huth, Head of External Affairs, Center for Innovation & Value Research

Guests:

• Maia Laing, Chief Policy Officer, SickCells
• Silas Martin, Head of Access & Policy Research, Johnson & Johnson

Episode Summary

This episode explores how drug pricing reform can move beyond price to better reflect patient-centered value. Recorded following the 2025 Fall Policy Summit, the discussion examines the role of lived experience, evidence, and innovation in shaping more equitable, sustainable drug pricing policy.

What You’ll Hear

• Why patient-centered value must be central to drug pricing reform
• Where international pricing comparisons fall short for U.S. patients
• How affordability, access, and innovation can coexist
• The importance of patient-generated evidence alongside economic models

Related Resources & Events

J&J Center for U.S. Healthcare Policy Research:
https://policyresearch.jnj.com/

Why Accounting for Heterogeneity Matters in U.S. Economic Analyses:
https://policyresearch.jnj.com/why-accounting-for-heterogeneity-matters-in-u-s-economic-analyses

SickCells Policy Forum (March 17–18) – Registration now open https://sickcells.org/policy-forum/

Center’s 2026 7th Annual Methods Summit
Valuing Innovation: Expanding Definitions of Value

Wednesday, March 25, 2026, 9:00 AM – 5:00 PM EDT

USC Capital Campus, Washington, DC 

Register now to attend in-person or via livestream.